Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer

Inclusion Criteria:

- Subjects must be currently participating in the 20040138 Amgen study

- Subjects must sign the informed consent before any study specific procedures are
performed.

Exclusion Criteria

- Subjects with any prior diagnosis of bone metastasis

- Known hypocalcemia

- Developed sensitivity to mammalian cell derived drug products during the 20040138
study

- Currently receiving any investigational product other than denosumab or having
received any investigational product during the 20040138 study

- Any disorder that, in the opinion of the investigator, may compromise the ability of
the subject to give written informed consent and/or comply with study procedures